ENTADFI
Peakfinasteride; tadalafil
NDAORALCAPSULE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ENTADFI (finasteride; tadalafil) is tadalafil. First approved in 2021.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTADFI is an oral fixed-dose combination of finasteride (a Type II 5α-reductase inhibitor) and tadalafil (a PDE5 inhibitor) approved for benign prostatic hyperplasia (BPH). Finasteride reduces DHT-driven prostate enlargement by inhibiting testosterone metabolism, while tadalafil relaxes smooth muscle in the prostate and bladder via phosphodiesterase inhibition. This combination addresses both the obstructive (mechanical) and dynamic (smooth muscle tone) components of BPH symptoms.
Peak
Product is at peak lifecycle stage; commercial teams are focused on market penetration and competitive positioning in the BPH space.
Mechanism of Action
tadalafil. Finasteride: The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.